GlassScriptPhysician profile
Joseph M Duva
NPI 1992817977
$11,208.30
in general payments reported to CMS, 2019-2025
32 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $823 · 2021: $1,723 · 2022: $1,314 · 2023: $1,924 · 2024: $1,649 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,797 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,796.56 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,156.03 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $1,893.02 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $1,498.93 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $972.69 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Nestle Healthcare Nutrition INC. | $463.70 | 2021-2023 | |
| Romark Laboratories, Lc | $412.56 | 2019 | |
| Redhill Biopharma INC. | $389.47 | 2020-2024 | Talicia |
| Madrigal Pharmaceuticals | $358.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $354.19 | 2019-2024 | Injectafer |
| Janssen Biotech, INC. | $322.67 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $294.72 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $261.31 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $245.06 | 2019-2023 | Linzess |
| Thd America, INC. | $183.06 | 2025 | |
| Ardelyx, INC. | $169.93 | 2022-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $164.14 | 2019-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $163.27 | 2019-2023 | Rebyota |
| Exact Sciences Corporation | $163.07 | 2024-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $142.01 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $126.39 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $121.26 | 2022-2023 | Zeposia |
| Alfasigma USA, INC. | $73.34 | 2020-2021 | |
| Concordia Pharmaceuticals INC. | $56.75 | 2019 | |
| Paratek Pharmaceuticals, INC. | $42.21 | 2025 | Nuzyra |
| Celltrion USA INC. | $39.62 | 2024 | Zymfentra |
| Vivus LLC | $33.82 | 2021-2025 | Pancreaze |
| Lilly USA, LLC | $25.01 | 2025 | Omvoh |
| Shield Therapeutics INC | $18.39 | 2024 | |
| Vyera Pharmaceuticals, LLC | $17.83 | 2019 | |
| Viiv Healthcare Company | $16.99 | 2024 | Rukobia |
| Axonics, INC. | $16.87 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Duva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.